NYSE - Nasdaq Real Time Price
USD
Stevanato Group S.p.A. (STVN)
20.45
-0.10
(-0.46%)
As of 10:52:52 AM EDT. Market Open.
Trade STVN on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for STVN
- Previous Close
20.54 - Open
20.26 - Bid 20.27 x 20000
- Ask 20.50 x 30000
- Day's Range
20.02 - 20.57 - 52 Week Range
12.89 - 28.00 - Volume
14,630 - Avg. Volume
397,093 - Market Cap (intraday)
5.582B - Beta (5Y Monthly) 0.75
- PE Ratio (TTM)
35.87 - EPS (TTM)
0.57 - Earnings Date Nov 5, 2026
- Forward Dividend & Yield 0.06 (0.30%)
- Ex-Dividend Date Jun 11, 2026
- 1y Target Est
24.83
Recent News
View More
Performance Overview
Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
STVN
1.98%
S&P 500 (^GSPC)
12.68%
1-Year Return
STVN
10.94%
S&P 500 (^GSPC)
18.63%
3-Year Return
STVN
37.99%
S&P 500 (^GSPC)
70.81%
5-Year Return
STVN
24.31%
S&P 500 (^GSPC)
70.07%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 9/1/2026
-
Market Cap
5.66B
-
Enterprise Value
6.07B
-
Trailing P/E
36.47
-
Forward P/E
27.78
-
PEG Ratio (5yr expected)
1.49
-
Price/Sales (ttm)
3.98
-
Price/Book (mrq)
3.15
-
Enterprise Value/Revenue
4.27
-
Enterprise Value/EBITDA
17.83
Financial Highlights
Profitability and Income Statement
-
Profit Margin
10.99%
-
Return on Assets (ttm)
5.45%
-
Return on Equity (ttm)
9.13%
-
Revenue (ttm)
1.23B
-
Net Income Avi to Common (ttm)
134.61M
-
Diluted EPS (ttm)
0.57
Balance Sheet and Cash Flow
-
Total Cash (mrq)
79.14M
-
Total Debt/Equity (mrq)
28.73%
-
Levered Free Cash Flow (ttm)
-104.7M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
342.41
-0.09%
Mkt Cap
24.097B
Industry
Medical Instruments & Supplies
27.27
-1.16%
Mkt Cap
4.38B
Industry
Medical Instruments & Supplies
191.20
-3.72%
Mkt Cap
EUR
18.6B
Industry
Medical Instruments & Supplies
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View More-
Stevanato: Initiating Coverage With a Narrow Moat and USD 21.10 FVE; Shares Fairly Valued
Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America.
RatingPrice Target -
Stevanato: Initiating Coverage With a Narrow Moat and USD 21.10 FVE; Shares Fairly Valued
Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America.
RatingPrice Target -
Dropping Coverage of Stevanato
Italy-based Stevanato Group is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. Stevanato’s revenue is geographically diversified, with 60% of sales from Europe, the Middle East and Africa (EMEA), 27% in North America, 10% in Asia-Pacific (APAC), and 3% in South America.
RatingPrice Target -
Stevanato's Sturdy Growth Shows No Signs of Slowing as Q2 Exceeds Forecasts; Shares Fairly Valued
Italy-based Stevanato Group is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. Stevanato’s revenue is geographically diversified, with 60% of sales from Europe, the Middle East and Africa (EMEA), 27% in North America, 10% in Asia-Pacific (APAC), and 3% in South America.
RatingPrice Target
